Skip to main content

Rapid Review Panel

Volume 457: debated on Tuesday 6 March 2007

To ask the Secretary of State for Health on which dates the Rapid Review Panel met since December 2003; how many product assessments the panel undertook since December 2003; how many assessed products were recommended to her Department for use in the NHS; how many products were recommended for use by the NHS Purchasing and Supplies Agency; and how many products in use by the NHS were recommended by the panel. (116151)

The Rapid Review Panel (RRP) has met 12 times since its first meeting. It met on the 24 August 2004, 29 November 2004, 26 January 2005, 24 February 2005, 25 May 2005, 14 July 2005, 18 October 20058, 23 March 2006, 9 May 2006, 7 July 2006, 21 September 2006 and 12 December 2006.

The panel has undertaken 168 assessments since its first meeting.

Three products have demonstrated sufficient basic research and development, validation and recent in use evaluations to enable the RRP to conclude that the products have shown benefits that should be available to the national health service.

The NHS Purchasing and Supplies Agency (PASA) does not recommend particular products. PASA’s Centre for Evidence-based Purchasing has published a report confirming that there is significant potential for benefit from using Bard catheters, which are one of the three recommendation one products (basic research and development, validation and recent in use evaluations have shown benefits that should be available to NHS bodies to include as appropriate in their cleaning, hygiene or infection control protocols). Early data suggest that NHS Supply Chain are supplying 31 trusts including some primary care trusts and hospitals with Bard catheters with sales totalling around 60,000.

The Department does not have full information on the use of these three recommendation one products as infection control products do not have to be purchased through NHS Supply Chain.

A number of recommendation two products (basic research and development has been completed and the product may have potential value; in use evaluations and trials are now needed in an NHS clinical setting) are already incorporated into NHS Supply Chain strategic resourcing arrangements, listed to be included in particular contracting rounds, or being evaluated in departmental funded studies.